Quick Takeaways
- Paul B. Manning has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $95,556,393.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Paul B. Manning
- Location
- Charlottesville, VA
- Summary
- The estimated net worth of Paul B. Manning is at least $95,556,393 dollars as of 02 Apr 2026. Paul B. Manning is the Director of Candel Therapeutics, Inc. and owns shares of Candel Therapeutics, Inc. (CADL) stock worth about $33.27M. Paul B. Manning is the Director, 10%+ Owner of Verrica Pharmaceuticals Inc. and owns shares of Verrica Pharmaceuticals Inc. (VRCA) stock worth about $32.17M. Paul B. Manning is the Director of Liquidia Corp and owns shares of Liquidia Corp (LQDA) stock worth about $20.02M. Paul B. Manning is the 10%+ Owner of Taysha Gene Therapies, Inc. and owns shares of Taysha Gene Therapies, Inc. (TSHA) stock worth about $7.81M. Paul B. Manning is the 10%+ Owner of Acumen Pharmaceuticals, Inc. and owns shares of Acumen Pharmaceuticals, Inc. (ABOS) stock worth about $2.28M.
- Signature
- /s/ Charles Schoch, as Attorney-In-Fact for Paul B. Manning
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Paul B. Manning and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Candel Therapeutics, Inc. ($33,268,209).
- Past-year value change for that position: +$2,999,996.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Paul B. Manning
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | Director | $33,268,209 | +$2,999,996 | +9.9% | 31 Mar 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | $32,171,572 | +$17,505,157 | +119% | 25 Nov 2025 |
| LQDA | Liquidia Corp | Director | $20,018,323 | -$18,957,475 | -49% | 11 Feb 2026 |
| TSHA | Taysha Gene Therapies, Inc. | 10%+ Owner | $7,814,686 | +$2,062,500 | +36% | 30 May 2025 |
| ABOS | Acumen Pharmaceuticals, Inc. | 10%+ Owner | $2,283,603 | 06 Jul 2021 |
Insider Transactions Reported by Paul B. Manning:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.